Figure 6.

GBP1 influences chemotherapy response

(A–D) 100–300 transduced OC cells/well were plated in 12 well tissue culture plates followed by treatment with paclitaxel (ID8-15 nM and OVCAR8-7.5 nM) after 24 h and allowed to grow for 7–10 days. Colonies were stained using crystal violet and confluency was measured. Data are shown as mean ± SD of triplicate samples. Significant differences compared to respective controls were assessed by Student’s t test.

(E) Immunoblotting of total ubiquitinated proteins in transduced OC cells treated with vehicle (DMSO) (C) or paclitaxel (ID8-15 nM and OVCAR8-7.5 nM) for 24 h.

(F–I) Kaplan-Meier plots (KMplot) for the probability of survival of ovarian cancer patients with GBP1-high (high) and GBP1-low (low) expression (mRNA gene chip data, Affy ID: 202269_x_at). KMplots were plotted using KM-plotter.

(F) KMplot (n = 1435) of ovarian cancer patients with high and low GBP1 expression. The plot includes patients of all the stages (1–4) of ovarian cancer.

(G) KMplot (n = 163) of ovarian cancer patients with disease at stages 1 and 2 with high and low GBP1 expression.

(H) KMplot (n = 73) of ovarian cancer patients with disease at stages 1 and 2 and treated with Taxol with high and low GBP1 expression.

(I) KMplot (n = 94) of ovarian cancer patients with disease at stages 1 and 2 and treated with platinum agents with high and low GBP1 expression.